Get App
Download App Scanner
Scan to Download
Advertisement
This Article is From Mar 12, 2025

India Pharma — Slowdown Across Categories Drags IPM Growth In February: ICICI Securities

Better traction in cardiac brands drove outperformance for JB Chemicals, Ipca, Zydus, Mankind, Glenmark, Lupin and Pfizer, says ICICI Securities.

India Pharma — Slowdown Across Categories Drags IPM Growth In February: ICICI Securities
As per IQVIA, revenue of the domestic pharma market stood at Rs187 billion, up 4.1% YoY in Feb’25, mainly driven by price-led growth while volume receded 1.4%.(Photo Source: Freepik)
STOCKS IN THIS STORY
Ajanta Pharma Ltd.
--
Pfizer Ltd.
--
Sanofi Consumer Healthcare India Ltd
--
Eris Lifesciences Ltd.
--
Indoco Remedies Ltd.
--
Alembic Pharmaceuticals Ltd.
--
Cipla Ltd.
--
Alkem Laboratories Ltd.
--
Sun Pharmaceutical Industries Ltd.
--
Abbott India Ltd.
--
Mankind Pharma Ltd
--
Glaxosmithkline Pharmaceuticals Ltd.
--
JB Chemicals & Pharmaceuticals Ltd.
--
Torrent Pharmaceuticals Ltd.
--
Ipca Laboratories Ltd.
--
Zydus Lifesciences Ltd.
--

Volumes for the industry declined by 1.4% YoY. Barring Ipca Labs (+2.7%) and Mankind Pharma (+0.6%), Feb'25 volume growth of other companies either was flattish or declined.

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Securities Report

As per IQVIA, the Indian pharma market grew 4.1% YoY (-3.7% month-on-month) in February 2025. Growth across segments slowed in Feb'25. For the month, chronic therapies grew at a modest 5% YoY while acute therapies' sales growth came in lower at 3%.

Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay

Volumes for the industry declined by 1.4% YoY. Barring Ipca Labs (+2.7%) and Mankind Pharma (+0.6%), Feb'25 volume growth of other companies either was flattish or declined.

Among key therapies, urology grew the fastest at 9.5%, followed by gastro-intestinal (+7.8%) and cardiac (+7.2%). Sales of top molecules of other therapies slackened in Feb'25.

Better traction in cardiac brands drove outperformance for JB Chemicals, Ipca, Zydus, Mankind, Glenmark, Lupin and Pfizer. Alembic and GSK were among the few companies whose sales declined 4.7% and 5.1%, respectively.

Click on the attachment to read the full report:

ICICI Securities Pharma_sector_updt_Mar25.pdf
VIEW DOCUMENT

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices, Watch Business News Live and Latest Stories — On NDTV Profit.

Unlock the Full Story
with Premium Access
Already a subscriber? Sign In

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search
Loading PDF...
Listen to the latest songs, only on JioSaavn.com